BioArctic AB (publ) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in ...
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...
BioArctic AB (publ) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET. In conjunction to the report, BioArctic invites ...
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
Shares of Disc Medicine Inc. (NASDAQ:IRON) were trading at $56.94, up $9.81, or 20%, after the firm disclosed positive feedback from its end-of-phase II meeting with the FDA, supporting the regulatory ...
A year out from Leqembi’s approval for Alzheimer’s disease (AD), ongoing research coupled with artificial intelligence is ...
On November 2, the Cenla Walk to End Alzheimer’s Association held its annual walk at Fort Randolph in Pineville.
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...
If you'd like to learn more or get involved, the Dallas Walk to End Alzheimer's starts Saturday morning at 8:30 at Dallas ...
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) ...
Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback